FDA 503A Category 2 (April 2026) On April 15, 2026, the FDA published a 503A bulks list update
If your employer's plan excludes anti-obesity medications entirely (common in self-insured plans), your options are: the cash-pay manufacturer programs described above, asking your HR department whether the exclusion can be reconsidered (especially if your employer is large enough to modify the plan), or using the medication under a different indication (for example, Ozempic for type 2 diabetes, if applicable)
Toppings such as nuts add texture but also extra richness, so they're best used sparingly or skipped if heaviness is an issue
While the degree of change in BMI in published case reports, case series, and RCTs are inconclusive, GLP-1RAs may offer a new approach to HO treatment as the action of GLP-1 on appetite and energy regulation combines hypothalamic signaling and pathways that are independent of hypothalamic signaling
If that describes you, consider asking your clinician whether your eye history changes the risk calculation, whether you should have a baseline eye exam now, and whether there are alternative diabetes medications that better fit your situation
10.3389/fnins.2024.1463038 Front
